Cost of Revenue Trends: AbbVie Inc. vs Wave Life Sciences Ltd.

Comparing Cost Trends: AbbVie vs. Wave Life Sciences

__timestamp	AbbVie Inc.	Wave Life Sciences Ltd.
Wednesday, January 1, 2014	4426000000	2395000
Thursday, January 1, 2015	4500000000	9057000
Friday, January 1, 2016	5833000000	393000
Sunday, January 1, 2017	7040000000	79309000
Monday, January 1, 2018	7718000000	134428000
Tuesday, January 1, 2019	7439000000	175431000
Wednesday, January 1, 2020	15387000000	124165000
Friday, January 1, 2021	17446000000	121875000
Saturday, January 1, 2022	17414000000	10114000
Sunday, January 1, 2023	20415000000	9206000
Monday, January 1, 2024	0

Infusing magic into the data realm

Cost of Revenue: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding cost dynamics is crucial. AbbVie Inc., a global biopharmaceutical leader, and Wave Life Sciences Ltd., a cutting-edge biotech firm, present a fascinating contrast in cost of revenue trends from 2014 to 2023.

AbbVie Inc.: A Steady Climb

AbbVie has seen a consistent rise in its cost of revenue, peaking at approximately $20 billion in 2023. This represents a nearly 360% increase from 2014, reflecting its expansive growth and investment in research and development.

Wave Life Sciences Ltd.: A Volatile Journey

Conversely, Wave Life Sciences experienced a more volatile trajectory, with costs fluctuating significantly. Despite a peak in 2019, costs have since stabilized, indicating strategic adjustments.

This comparison underscores the diverse strategies and challenges faced by companies in the pharmaceutical and biotech industries.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025